Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company in Australia.
Universal Biosensors Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.79|
|52 Week High||AU$0.29|
|52 Week Low||AU$0.97|
|1 Month Change||-12.78%|
|3 Month Change||0%|
|1 Year Change||161.67%|
|3 Year Change||248.89%|
|5 Year Change||134.33%|
|Change since IPO||-21.50%|
Recent News & Updates
We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, Universal...
|UBI||AU Medical Equipment||AU Market|
Return vs Industry: UBI exceeded the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: UBI exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: UBI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: UBI's weekly volatility (7%) has been stable over the past year.
About the Company
Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It offers SENTIA Wine Analyzer to test Free Sulphur Dioxide; prothrombin time international normalized ratio coagulation test strips; Sentia Free Sulphite test strips; and coagulation testing and calibration services, as well as distributes Siemens’ Xprecia Stride Coagulation Analyzer.
Universal Biosensors Fundamentals Summary
|UBI fundamental statistics|
Is UBI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UBI income statement (TTM)|
|Cost of Revenue||AU$3.41m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.036|
|Net Profit Margin||-114.36%|
How did UBI perform over the long term?See historical performance and comparison
Is Universal Biosensors undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate UBI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate UBI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: UBI is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: UBI is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UBI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UBI is good value based on its PB Ratio (4x) compared to the AU Medical Equipment industry average (4.5x).
How is Universal Biosensors forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Universal Biosensors has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Universal Biosensors performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UBI is currently unprofitable.
Growing Profit Margin: UBI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UBI is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare UBI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UBI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: UBI has a negative Return on Equity (-18.16%), as it is currently unprofitable.
How is Universal Biosensors's financial position?
Financial Position Analysis
Short Term Liabilities: UBI's short term assets (A$28.4M) exceed its short term liabilities (A$7.6M).
Long Term Liabilities: UBI's short term assets (A$28.4M) exceed its long term liabilities (A$7.7M).
Debt to Equity History and Analysis
Debt Level: UBI's debt to equity ratio (0.2%) is considered satisfactory.
Reducing Debt: UBI's debt to equity ratio has reduced from 191.1% to 0.2% over the past 5 years.
Debt Coverage: UBI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if UBI's interest payments on its debt are well covered by EBIT.
What is Universal Biosensors's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UBI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UBI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UBI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Sharman (55 yo)
Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, serves as Non-Executive Director at Cann Group Limited since April 27, 2021. He serves as Chief Executive Officer at Universal Biosensors, Inc. since 2020. He...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD516.88K) is above average for companies of similar size in the Australian market ($USD302.45K).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
Experienced Management: UBI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: UBI's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Universal Biosensors, Inc.'s employee growth, exchange listings and data sources
- Name: Universal Biosensors, Inc.
- Ticker: UBI
- Exchange: ASX
- Founded: 2001
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$139.572m
- Shares outstanding: 177.80m
- Website: https://www.universalbiosensors.com
Number of Employees
- Universal Biosensors, Inc.
- 1 Corporate Avenue
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.